Finally, an anti-tumor activity of TRAIL/TNFSF10 in cholangiocarcinoma can also rely on additional mechanisms, namely activation of other TRAIL receptors than TRAIL-R1/TNFRSF10A, and targeting of other tumor promoting cells than just the tumor cells (44). The gene discussed is TNFSF10; the disease is neoplasm.